Concomitant Pathologies and Their Impact on Parkinson Disease: A Narrative Overview of Current Evidence
International Journal of Molecular Sciences · 24.03.2025 · 26 (7) · 2942
DOI: 10.3390/ijms26072942 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.03.2025. Verfasst von Kurt A Jellinger. Beteiligte Einrichtung: Institute of Clinical Neurobiology, Alberichgasse 5/13, A-1150 Vienna, Austria. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 305 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Society for the Promotion of Research in Experimental Neurology, Vienna, Austria.
Abstract (Originalsprache)
Many clinico-pathological studies point to the presence of multiple comorbidities/co-pathologies in the course of Parkinson disease (PD). Lewy body pathology, the morphological hallmark of PD, rarely exists in isolation, but is usually associated with other concomitant pathologies, in particular Alzheimer disease-related changes (ADNC), cerebrovascular pathologies (macro- and microinfarcts, cerebral small vessel disease, cerebral amyloid angiopathy), TDP-43 pathology as well as multiple pathological combinations. These include cardiovascular disorders, metabolic syndrome, diabetes mellitus, autoimmune and rheumatic diseases, myasthenia gravis, Sjögren’s syndrome, restless leg syndrome or other rare disorders, like Fabry disease. A combination of PD and multiple sclerosis (MS) may be due to the immune function of LRRK2 and its interrelation with α-synuclein. COVID-19 and HIV posed considerable impacts on patients with PD. Epidemiological evidence points to a decreased risk for the majority of neoplasms, except melanoma and other skin cancers, while some tumors (breast, brain) are increased. On the other hand, a lower frequency of malignancies preceding early PD markers may argue for their protective effect on PD risk. Possible pathogenetic factors for the association between PD and cancer are discussed. The tremendous heterogeneity of concomitant pathologies and comorbidities observed across the PD spectrum is most likely caused by the complex interplay between genetic, pathogenic and other risk factors, and further research should provide increasing insight into their relationship with idiopathic PD (and other parkinsonian disorders) in order to find better diagnostic tools and probable disease-modifying therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Neurobiology, Alberichgasse 5/13, A-1150 Vienna, Austria.
ORCID-Profile: Kurt A Jellinger
Förderung
- Society for the Promotion of Research in Experimental Neurology, Vienna, Austria
Zitieren
APA
Jellinger, K. A. (2025). Concomitant Pathologies and Their Impact on Parkinson Disease: A Narrative Overview of Current Evidence. International Journal of Molecular Sciences, 26(7), 2942. https://doi.org/10.3390/ijms26072942
Vancouver
Jellinger KA. Concomitant Pathologies and Their Impact on Parkinson Disease: A Narrative Overview of Current Evidence. International Journal of Molecular Sciences. 2025;26(7):2942. doi:10.3390/ijms26072942
BibTeX
@article{Jellinger2025,
author = {Jellinger, Kurt A},
title = {Concomitant Pathologies and Their Impact on Parkinson Disease: A Narrative Overview of Current Evidence},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {7},
pages = {2942},
doi = {10.3390/ijms26072942}
}
EUVIMED